Gemcitabine-cisplatin induction treatment in patients with locally advanced perihilar cholangiocarcinoma (IMPACCA): A prospective registration study

B. Ten Haaft(Amsterdam University Medical Centers), Joris I. Erdmann(Amsterdam University Medical Centers), Mahsoem Ali(Vrije Universiteit Amsterdam), Heinz‐Josef Klümpen(Amsterdam University Medical Centers), Geert Kazemier(Amsterdam Neuroscience), Lynn E. Nooijen(Amsterdam University Medical Centers), Barbara M. Zonderhuis(Amsterdam Neuroscience), Johanna W. Wilmink(Amsterdam University Medical Centers), Marc G. Besselink, Mélise M.T. Sickmann(Amsterdam University Medical Centers), Rutger‐Jan Swijnenburg(Amsterdam University Medical Centers)
European Journal of Surgical Oncology
November 6, 2024
10.1016/j.ejso.2024.109358
Cited by 4

Related Papers

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1k
Endoscopic Transgastric vs Surgical Necrosectomy for Infected Necrotizing Pancreatitis
|JAMA|2012|735
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|715
United European Gastroenterology evidence‐based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)
|United European Gastroenterology Journal|2017|698
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530